Publicaciones en las que colabora con Bonaventura Casanova Estruch (22)

2023

  1. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience

    Frontiers in Neurology, Vol. 14

2022

  1. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

    Journal of Neurology, Vol. 269, Núm. 7, pp. 3676-3681

  2. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis

    Frontiers in Immunology, Vol. 13

  3. NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity

    Journal of Neurology, Vol. 269, Núm. 7, pp. 3495-3500

  4. Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis

    Frontiers in Neurology, Vol. 13

2021

  1. Potential Role of CHI3L1+ Astrocytes in Progression in MS

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 8, Núm. 3

  2. Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain

    Frontiers in Neurology, Vol. 12

2020

  1. CSF chitinase 3-like-1 association with disability of primary progressive MS

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 7, Núm. 5

  2. Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF-α treatment

    Journal of Hepatology, Vol. 73, Núm. 3, pp. 582-592

  3. Reader response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis

    Neurology

  4. Sustained hyperammonemia induces TNF-A in Purkinje neurons by activating the TNFR1-NF-κB pathway

    Journal of Neuroinflammation, Vol. 17, Núm. 1

2019

  1. Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype

    Frontiers in Neurology, Vol. 10

  2. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis

    Frontiers in Neurology, Vol. 10

  3. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

    Multiple Sclerosis and Related Disorders, Vol. 27, pp. 406-408

  4. Silent Progression or Bout Onset Progressive Multiple Sclerosis?

    Annals of Neurology

  5. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe

    Journal of Neurology, Vol. 266, Núm. 3, pp. 726-734

2018

  1. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

    Journal of Neurology, Vol. 265, Núm. 7, pp. 1690-1697

  2. Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 4, Núm. 2

  3. Progressive demyelination in the presence of serum myelin oligodendrocyte glycoprotein-IgG: A case report

    Frontiers in Neurology, Vol. 9, Núm. MAY

2017

  1. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

    Neurological Sciences, Vol. 38, Núm. 7, pp. 1213-1221